Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21677275 | 0.78 | NLRP3 (0.39) | PARP10NLRP3GAA | |
| SCHEMBL21677312 | 0.78 | NLRP3 (0.33) | PARP10NLRP3GAA | |
| SCHEMBL21677206 | 0.77 | NLRP3 (0.39) | PARP10NLRP3GAA | |
| SCHEMBL23881934 | 0.77 | NLRP3 (0.42) | PARP10NLRP3GAA | |
| SCHEMBL21677272 | 0.74 | — | — | |
| SCHEMBL25362764 | 0.69 | GAA (0.35) | NLRP3GAA | |
| SCHEMBL21677365 | 0.63 | GFER (0.37) | PARP10NLRP3GAA | |
| SCHEMBL21677370 | 0.62 | NLRP3 (0.39) | NLRP3 | |
| SCHEMBL21677309 | 0.62 | NLRP3 (0.45) | PARP10NLRP3GAA | |
| SCHEMBL21677204 | 0.61 | NLRP3 (0.42) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168012-B2 | NLRP3 inflammasome inhibitors | NOVARTIS AG (CH) | 2024-12-17 | — | — | US | disclosed |
| EP-3827008-B1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| US-20210308140-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| US-20210308140-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| WO-2020021447-A1 | NLRP3 INFLAMMASOME INHIBITORS | NOVARTIS AG (CH) | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168012-B2 | NLRP3 inflammasome inhibitors | NLRP3, NLRP1, NOD1 | PARP10 456/4885NLRP3 1/4885GAA 4407/4885 |
| US-20210308140-A1 | NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, NOD1 | PARP10 468/4885NLRP3 1/4885GAA 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.